CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,313 enrolled
Drug / intervention
TAK-700 +1 moredrug
Likely dose
TAK-700 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01809691
NCT01809691Phase 3Completed
CompareCT.gov

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

SWOG Cancer Research Network·interventional·Posted Mar 13, 2013·Updated Dec 31, 2025

In Brief

A Phase 3 clinical trial evaluating TAK-700 and Bicalutamide for Prostate Cancer. Completed, enrolled 1,313 participants across 560 sites.

Detailed Summary

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc., National Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2013
Enrollment StartMar 8, 2013
Primary CompletionMar 8, 2022
Study CompletionSep 9, 2025
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 13.3 years ago

Interventions

TAK-700drug

300 mg, PO, twice daily

Bicalutamidedrug

50 mg, PO, q daily